Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols

Andrea Pession, R. Rondelli, G. Basso, C. Rizzari, A. M. Testi, F. Fagioli, P. De Stefano, F. Locatelli

Research output: Contribution to journalArticle

Abstract

Since 1982, four consecutive studies on childhood acute myeloid leukaemia (AML) (namely LAM-82, -87, -87M and -92) have been conducted in Italy by the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) group. The induction therapy of the first three studies consisted of daunorubicin and cytarabine structured in a 3+7 backbone. In the most recent protocol (LAM92), patients received two induction courses including idarubicin, cytarabine and etoposide. Patients with acute promyelocytic leukaemia (20% of diagnoses) were included in LAM-87 and 87M studies. Postremissional therapy significantly changed over time, with an ever-increasing role given to stem cell transplantation (SCT). The long-term outcome of patients enrolled in the LAM-82, 87 and 87M studies was comparable, whereas that of children treated according to LAM-92 study was significantly better (P

Original languageEnglish
Pages (from-to)2043-2053
Number of pages11
JournalLeukemia
Volume19
Issue number12
DOIs
Publication statusPublished - Dec 2005

    Fingerprint

Keywords

  • Acute promyelocytic luekemia
  • Childhood acute myeloid leukaemia
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Pession, A., Rondelli, R., Basso, G., Rizzari, C., Testi, A. M., Fagioli, F., De Stefano, P., & Locatelli, F. (2005). Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia, 19(12), 2043-2053. https://doi.org/10.1038/sj.leu.2403869